- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04643847
A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases
November 19, 2020 updated by: First People's Hospital of Hangzhou
Upfront Radiotherapy Combined With Almonertinib for Brain Metastasis in Non-small Cell Lung Cancer With EGFR Mutation: A Prospective Single-arm Phase II Trial
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs.
This study intends to assess the efficacy and safety of stereotactic radiosurgery with sequential almonertinib in treatment-naive EGFR-mutant NSCLC patients with brain metastases.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
47
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Bing Xia, MD
- Phone Number: 86 571 56006388
- Email: bxia_hzch@hotmail.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310002
- Hangzhou Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or pathologically confirmed non-small-cell lung cancer (adenocarcinoma).
- The presence of radiographically definite brain metastases and intracranial foci measurable according to the RANO-BM criteria.
- The number of brain metastases ≤ 10, the volume of individual metastases ≤ 15 cc, the diameter of individual metastases ≤ 30 mm, the diameter of metastases in the brainstem ≤ 5 mm, distance of the foci from the optic nerve, or optic cross > 5 mm.
- EGFR-sensitive mutations (include 19del or L858R mutation or coexist with other types of EGFR mutation).
- Comply with the indications and drug instructions for first-line treatment with a third-generation EGFR-TKI.
- Have not received systemic antineoplastic therapy, excluding neoadjuvant, adjuvant, or synchronous chemotherapy more than 6 months prior to enrollment.
- Asymptomatic or mildly symptomatic brain metastases (e.g., headache, nausea, or seizures for which dexamethasone/analgesic/antiepileptic medication is effective and sustained at a steady dose for 3 days or more).
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status(PS) score ≤ 2.
- Survival is expected to be ≥ 6 months.
- Women must use contraception after surgical sterilization, after sterilization, or during and for three months after treatment.
- With informed consent signed.
Exclusion Criteria:
- Previous treatment with almonertinib or other EGFR-TKI.
- Patients with symptomatic brain metastases resulting in neurological deficits (not including headaches, nausea, or controlled seizures).
- Multiple sclerosis.
- Pacemakers implanted in the body or metals that cannot be examined by MRI.
- Allergy to magnetic resonance contrast agents.
- Brain metastases requiring surgical decompression.
- Meningeal metastases.
- Previous radiotherapy or surgery for brain metastases.
- Contraindications to radiotherapy for uncontrolled systemic lupus erythematosus, scleroderma, or other connective tissue diseases.
- Other malignant neoplasms (except non-melanoma skin cancer and cervical cancer) within five years.
- Any medical or non-medical reason that prevents the patient from continuing to participate in research.
- It is expected that the patient will not be able to comply with the procedures, restrictions, and requirements of the study and the investigator determines that the patient is unfit to participate in the study.
- Received studying drugs within 5 half-lives or 3 months, whichever is greater.
- Currently receiving drugs or herbal supplements known to be potent inducers of Cytochrome P450 3A4(CYP3A4) or unable to be discontinued prior to receiving the first dose of study treatment) (at least 3 weeks prior).
- The patient is taking any drug known to prolong the QT interval and cannot be discontinued until treatment with amitriptyline.
- Pregnancy or breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stereotactic radiosurgery with Almonertinib
110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment).
For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions
|
110mg Almonertinib is administered orally daily since the first day after stereotactic radiosurgery treatment (total dose 30 Gy, 5 fractions, day1, 3, 5, calibrated by CBCT before each treatment).
For patients who are assessed as oligometastasis three months after Almonertinib treatment, SBRT is recommended for oligometastatic lesions (The number of lesions received SBRT and radiation dose are not standardized).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Central nerve system duration of response(CNS DOR)
Time Frame: 1 year
|
Central nerve system duration of response assessed by RANO-BM criteria
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intracranial prgression-free survival(PFS)
Time Frame: 1 year
|
Intracranial progression free survival assessed by Response Assessment in Neuro-Oncology Brain Metastases(RANO-BM) criteria
|
1 year
|
Intracranial response rate(RR)
Time Frame: 1 year
|
Intracranial response rate assessed by RANO-BM criteria
|
1 year
|
Extracranial RR
Time Frame: 1 year
|
Extracranial response rate assessed by Response Evaluation Criteria in Solid Tumors(RECIST) criteria
|
1 year
|
overall survival (OS)
Time Frame: 1 year
|
overall survival
|
1 year
|
Neurocognitive function assessed by mini-mental state examination(MMSE) questionnaire score
Time Frame: 1 year
|
Neurocognitive function assessed by mini-mental state examination(MMSE) questionnaire score
|
1 year
|
quality of life(QoL) assessed by EORTC QLQ-C30
Time Frame: 1 year
|
Quality of Life assessed by The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30(EORTC QLQ-C30)
|
1 year
|
quality of life(QoL) assessed by EORTC QLQ-BN20
Time Frame: 1 year
|
Quality of Life assessed by The European Organization for Reasearch and Treatment of Cancer Quality of Life Questionnaire Brain Cancer 20(BN20)
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intracranial RR accessed by volumetric criteria
Time Frame: 1 year
|
Intracranial response rate accessed by volumetric criteria
|
1 year
|
intracranial progression rate assessed by brain MRI at 1year
Time Frame: 1 year
|
intracranial progression rate assessed by brain MRI at 1year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 30, 2020
Primary Completion (Anticipated)
November 30, 2022
Study Completion (Anticipated)
November 30, 2023
Study Registration Dates
First Submitted
November 15, 2020
First Submitted That Met QC Criteria
November 19, 2020
First Posted (Actual)
November 25, 2020
Study Record Updates
Last Update Posted (Actual)
November 25, 2020
Last Update Submitted That Met QC Criteria
November 19, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis
- Brain Neoplasms
Other Study ID Numbers
- AlmonRad
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Metastases
-
AC Camargo Cancer CenterCarl Zeiss Meditec AGTerminatedBrain Metastases, Adult | Central Nervous System MetastasesBrazil
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRecurrent Brain Metastases | Progressive Brain MetastasesUnited States
-
Istituto Clinico HumanitasRecruitingBrain Metastases, AdultItaly
-
Mustafa Khasraw, MBChB, MD, FRCP, FRACPDaiichi SankyoNot yet recruitingA Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer)Brain Metastases, AdultUnited States
-
Istituto Clinico HumanitasBrainlabRecruitingBrain Metastases, AdultItaly
-
Universitaire Ziekenhuizen KU LeuvenRecruitingBrain Metastases, AdultBelgium
-
University Hospital, GrenobleNH TherAguix SASRecruitingRadiotherapy | Brain Metastases, AdultFrance
-
Centre de recherche du Centre hospitalier universitaire...Université de SherbrookeActive, not recruitingBrain Metastases, AdultCanada
-
Juergen DebusHeidelberg UniversityCompletedBrain Metastases, AdultGermany
-
Instituto de Oncología Ángel H. RoffoCompletedUnresectable Multiple Brain Metastases
Clinical Trials on Almonertinib
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Active, not recruitingNon-small Cell Lung CancerChina
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruitingRelapsed or Advanced Non-small Cell Lung Cancer
-
Guangzhou Institute of Respiratory DiseaseRecruitingPoor Performance Status | Malignant Tumor of LungChina
-
Guangdong Association of Clinical TrialsJiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting
-
Shanghai Cancer Hospital, ChinaRecruitingNon-small Cell Lung Cancer MetastaticChina
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
Yuan ChenRecruitingNSCLC, Stage IIIChina
-
Sun Yat-sen UniversityEnrolling by invitation
-
GeneScience Pharmaceuticals Co., Ltd.RecruitingMetastatic Non-Small Cell Lung CancerChina